Return to site

TargaCell Improves Delivery of Stem Cells

Mark Holterman

Add paragraph text here.A professor of surgery and pediatrics at the University of Illinois College of Medicine, Dr. Mark Holterman is a graduate of Yale University and the University of Virginia. Frequently tapped for his medical expertise in regenerative medicine, Mark Holterman, MD, recently joined the board of managers of TargaCell.

Founded in 2011, TargaCell is a Chicago-based biotechnology company that offers a noninvasive system to deliver and retain adult stem cells in organs in order to repair organ damage. TargaCell’s method delivers the stem cells intravenously to patients in an outpatient procedure, which represents a significant improvement over the standard catheter-based delivery system.
The intravenous delivery approach reduces stem cell damage and loss and allows physicians to directly target the intended organ, which greatly increases the level of stem cell retention and improves the chances of organ repair. TargaCell’s technology also lowers treatment and recovery costs for patients with cardiovascular disease. Catherine Phillips, a former research professor of medicine at the University of Illinois at Chicago, founded TargaCell and now serves as its chief scientific officer.

All Posts

Almost done…

We just sent you an email. Please click the link in the email to confirm your subscription!

OKSubscriptions powered by Strikingly